MicrobeWorld App

appsquarebannerad200x200

Join MicrobeWorld

Subscribe via Email

subscribe

Microbes After Hours

shutdown

Click for more "Microbes After Hours" videos

Featured Image

Featured Video

Crowdsourced Microbes Heading to Station

Supporters

ASM House 200X200

Experimental antiviral drug boceprevir doubles cure rate for hepatitis C

An experimental antiviral agent called boceprevir doubled the cure rate for hepatitis C in a small phase 2 clinical trial designed to show efficacy, researchers reported Sunday. The drug will now be submitted to the larger Phase 3 trial required for approval of the drug by the Food and Drug Administration.

Hepatitis C is a chronic viral infection that affects an estimated 170 million people worldwide, leading eventually to cirrhosis and liver cancer if not controlled. The standard treatment now is a 48-week regimen of pegylated interferon, which boosts the immune system, and the antiviral agent ribavirin, which is a general-purpose antiviral agent. But the combination cures less than half of those who receive it and, for reasons that are not clear, is even less effective in African Americans. The most difficult strain to treat is the so-called genotype 1, which is the strain infecting about 70% of Americans.

Boceprevir, originally developed by Schering-Plough, which was recently purchased by Merck, is designed to attack the protease enzyme used by the hepatitis C virus to replicate. In that sense, it is analogous to the protease inhibitors, such as saquinavir and ritonavir, that revolutionized HIV treatment when used in conjunction with other AIDS drugs.
 
 

Comments (0)

Collections (0)

 

American Society for Microbiology
2012 1752 N Street, N.W. • Washington, DC 20036-2904 • (202) 737-3600

Copyright © American Center for Microbiology 2012. All Rights Reserved.